# clm_E31AD6E2CA61

subject: Eli Lilly and Company (/record/eli-lilly.md)  
predicate: quarterly_research_and_development  
value: 1,335,900,000 United States dollar  
valid_from: 2016-06-30  
valid_to: 2016-09-30  
published: 2016-07-28  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_A8E893E76F87  
last_updated: 2026-11-08  
cite: AsOf. "Eli Lilly and Company quarterly research and development: 1,335,900,000 United States dollar", as of 2016-06-30 (until 2016-09-30). Claim clm_E31AD6E2CA61, https://asof.is/claim/clm_E31AD6E2CA61, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2016, filed 2016-07-28  

## Sources

- https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm (primary, SEC EDGAR 10-Q Q2 FY2016, published 2016-07-28)

## Supersedes

- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_research_and_development | 1,221,000,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_E31AD6E2CA61](/claim/clm_E31AD6E2CA61.md) | [clm_0515A159428D](/claim/clm_0515A159428D.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.